News
Investor's Business Daily on MSN1h
Sarepta Topples, Again, After Refusing The FDA's Request To Pull ElevidysSarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...
The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the ...
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...
A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback